Endoglin expression in upper urinary tract urothelial carcinoma is associated with intravesical recurrence after radical nephroureterectomy

International Journal of Urology

Volumn 22, Issue 5, 2015, Pages 463-467

  Fujita, Kazutoshi ^a   Ujike, Takeshi ^a   Nagahara, Akira ^a   Uemura, Motohide ^a   Tanigawa, Go ^b   Shimazu, Kohki ^b   Fushimi, Hiroaki ^b   Yamaguchi, Seiji ^b   Nonomura, Norio ^a  

^a OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b OSAKA GENERAL MEDICAL CENTER   (Japan)

Author keywords

Endoglin; Immunohistochemistry; Intravesical recurrence; Nephroureterectomy; Upper urinary tract urothelial carcinoma

Indexed keywords

BIOLOGICAL MARKER; ENDOGLIN; CELL SURFACE RECEPTOR; ENG PROTEIN, HUMAN; LEUKOCYTE ANTIGEN; TUMOR MARKER;

ADULT; AGED; ARTICLE; CANCER GRADING; CANCER MORTALITY; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER STAGING; DISTANT METASTASIS; ENDOTHELIUM; FEMALE; FOLLOW UP; HAZARD RATIO; HUMAN; IMMUNOHISTOCHEMISTRY; INTRAVESICAL RECURRENCE; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; NEPHROURETERECTOMY; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECURRENCE FREE SURVIVAL; RISK FACTOR; TISSUE MICROARRAY; TRANSITIONAL CELL CARCINOMA; TUMOR LOCALIZATION; URINE CYTOLOGY; UROTHELIUM; VERY ELDERLY; CARCINOMA, TRANSITIONAL CELL; GENETICS; METABOLISM; MIDDLE AGED; NEPHRECTOMY; PATHOLOGY; PHOSPHORYLATION; PROGNOSIS; SIGNAL TRANSDUCTION; SURVIVAL; TUMOR RECURRENCE; URINARY TRACT; UROLOGIC NEOPLASMS;

AGED; AGED, 80 AND OVER; ANTIGENS, CD; BIOMARKERS, TUMOR; CARCINOMA, TRANSITIONAL CELL; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEPHRECTOMY; PHOSPHORYLATION; PROGNOSIS; RECEPTORS, CELL SURFACE; SIGNAL TRANSDUCTION; SURVIVAL ANALYSIS; URINARY TRACT; UROLOGIC NEOPLASMS; UROTHELIUM;

EID: 84928714026     PISSN: 09198172     EISSN: 14422042     Source Type: Journal    
DOI: 10.1111/iju.12719     Document Type: Article

References (23)

1. Green DA, Rink M, Xylinas E et al. Urothelial Carcinoma of the Bladder and the Upper Tract: Disparate Twins. J. Urol. 2012; 189: 1214-1221.
2. Oya M, Kikuchi E. Evidenced-based clinical practice guideline for upper tract urothelial carcinoma (summary - Japanese Urological Association, 2014 edition). Int. J. Urol. 2015; 22: 3-13.
3. Fujita K, Uemura M, Yamamoto Y et al. Preoperative risk stratification for cancer-specific survival of patients with upper urinary tract urothelial carcinoma treated by nephroureterectomy. Int. J. Clin. Oncol. 2014; doi: 10.1007/s10147-014-0695-1
4. Fujita K, Tanigawa G, Imamura R et al. Preoperative serum sodium is associated with cancer-specific survival in patients with upper urinary tract urothelial carcinoma treated by nephroureterectomy. Int. J. Urol. 2013; 20: 594-601.
5. Li DY, Sorensen LK, Brooke BS et al. Defective angiogenesis in mice lacking endoglin. Science 1999; 284: 1534-7.
6. Dubinski W, Gabril M, Iakovlev VV et al. Assessment of the prognostic significance of endoglin (CD105) in clear cell renal cell carcinoma using automated image analysis. Hum. Pathol. 2012; 43: 1037-43.
7. Takahashi N, Kawanishi-Tabata R, Haba A et al. Association of serum endoglin with metastasis in patients with colorectal, breast, and other solid tumors, and suppressive effect of chemotherapy on the serum endoglin. Clin. Cancer Res. 2001; 7: 524-32.
8. Fujita K, Ewing CM, Chan DYS et al. Endoglin (CD105) as a urinary and serum marker of prostate cancer. Int. J. Cancer 2009; 124: 664-9.
9. Rosen LS, Hurwitz HI, Wong MK et al. A phase I first-in-human study of TRC105 (Anti-Endoglin Antibody) in patients with advanced cancer. Clin. Cancer Res. 2012; 18: 4820-9.
10. Munari E, Fujita K, Faraj S et al. Dysregulation of mammalian target of rapamycin pathway in upper tract urothelial carcinoma. Hum. Pathol. 2013; 44: 2668-2676.
11. Zijlmans HJ, Fleuren GJ, Hazelbag S et al. Expression of endoglin (CD105) in cervical cancer. Br. J. Cancer 2009; 100: 1617-26.
12. El-Gohary YM, Silverman JF, Olson PR et al. Endoglin (CD105) and vascular endothelial growth factor as prognostic markers in prostatic adenocarcinoma. Am. J. Clin. Pathol. 2007; 127: 572-9.
13. Dales J-P, Garcia S, Bonnier P et al. CD105 expression is a marker of high metastatic risk and poor outcome in breast carcinomas. Correlations between immunohistochemical analysis and long-term follow-up in a series of 929 patients. Am. J. Clin. Pathol. 2003; 119: 374-80.
14. Saad RS, Liu YL, Nathan G, Celebrezze J, Medich D, Silverman JF. Endoglin (CD105) and vascular endothelial growth factor as prognostic markers in colorectal cancer. Mod. Pathol. 2004; 17: 197-203.
15. Kyzas PA, Agnantis NJ, Stefanou D. Endoglin (CD105) as a prognostic factor in head and neck squamous cell carcinoma. Virchows Arch. 2006; 448: 768-75.
16. Sandlund J, Hedberg Y, Bergh A, Grankvist K, Ljungberg B, Rasmuson T. Endoglin (CD105) expression in human renal cell carcinoma. BJU Int. 2006; 97: 706-10.
17. Agrawal U, Mishra AK, Salgia P, Verma S, Mohanty NK, Saxena S. Role of tumor suppressor and angiogenesis markers in prediction of recurrence of non muscle invasive bladder cancer. Pathol. Oncol. Res. 2011; 17: 91-101.
18. Santos L, Costa C, Pereira S et al. Neovascularisation is a prognostic factor of early recurrence in T1/G2 urothelial bladder tumours. Ann. Oncol. 2003; 14: 1419-1424.
19. Inoue K, Kamada M, Slaton JW, Yoshikawa C, Tamboli P. The Prognostic Value of Angiogenesis and Metastasis-related Genes for Progression of Transitional Cell Carcinoma of the Renal Pelvis and Ureter. Clin. Cancer Res. 2002; 8: 1863-1870.
20. Miyazaki Y, Kosaka T, Mikami S et al. The prognostic significance of vasohibin-1 expression in patients with upper urinary tract urothelial carcinoma. Clin. Cancer Res. 2012; 18: 4145-53.
21. Shirotake S, Miyajima A, Kosaka T et al. Angiotensin II type 1 receptor expression and microvessel density in human bladder cancer. Urology 2011; 77: 1009.e19-25.
22. Crew JP, O'Brien T, Bradburn M et al. Vascular endothelial growth factor is a predictor of relapse and stage progression in superficial bladder cancer. Cancer Res. 1997; 57: 5281-5.
23. Jeon SH, Lee SJ, Chang SG. Clinical significance of urinary vascular endothelial growth factor in patients with superficial bladder tumors. Oncol. Rep. 2001; 8: 1265-7.